Business Context and Reporting Period
This Form 8-K Current Report was filed by MaxCyte, Inc. (MXCT) on October 1, 2021, regarding events occurring on September 30, 2021. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC. MaxCyte is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is the departure of Dr. J. Stark Thompson from the Board of Directors. Dr. Thompson notified the Board on September 30, 2021, that he will not stand for re-election at the Annual Meeting of Stockholders scheduled for October 29, 2021. He will serve out his remaining term as a director and Chairman until the conclusion of the Annual Meeting. Following the meeting, the authorized Board size will be eight members, and a new Chairman will be appointed.
Guidance, Outlook, and Management Commentary
- Reason for Departure: The filing explicitly states that Dr. Thompson's decision is not related to any disagreement regarding the Company's operations, policies, or practices.
- Future Engagement: Dr. Thompson will continue to provide consulting services to the Company as requested. His outstanding stock option awards will continue to vest in accordance with their terms for as long as he provides continuous service.
- Management Statement: CEO Doug Doerfler expressed gratitude on behalf of the Board and the MaxCyte team for Dr. Thompson's service and guidance over the years.
Investor Verification Checklist
- Confirm the date and agenda of the Annual Meeting of Stockholders on October 29, 2021.
- Verify the appointment of the new Chairman of the Board following the Annual Meeting.
- Review the terms of Dr. Thompson's consulting agreement and the vesting schedule of his remaining stock options.
- Check for any subsequent filings regarding the composition of the Board of Directors.